2024
Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment
VÍTEČEK, Jan; Andrea VÍTEČKOVÁ WÜNSCHOVÁ; Sandra THALEROVÁ; Sumeet GULATI; Lukáš KUBALA et al.Základní údaje
Originální název
Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment
Autoři
VÍTEČEK, Jan; Andrea VÍTEČKOVÁ WÜNSCHOVÁ; Sandra THALEROVÁ; Sumeet GULATI; Lukáš KUBALA; Michaela CAPANDOVÁ; Aleš HAMPL a Robert MIKULÍK
Vydání
PLOS ONE, SAN FRANCISCO, PUBLIC LIBRARY SCIENCE, 2024, 1932-6203
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.600
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/24:00136220
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Blood Coagulation; Erythrocytes; Ischemic Stroke; Tissue Plasminogen Activator
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 4. 2025 12:31, Mgr. Tereza Miškechová
Anotace
V originále
Intravenous thrombolysis with a recombinant tissue plasminogen activator (rt-PA) is the first-line treatment of acute ischemic stroke. However, successful recanalization is relatively low and the underlying processes are not completely understood. The goal was to provide insights into clinically important factors potentially limiting rt-PA efficacy such as clot size, rt-PA concentration, clot age and also rt-PA in combination with heparin anticoagulant. We established a static in vitro thrombolytic model based on red blood cell (RBC) dominant clots prepared using spontaneous clotting from the blood of healthy donors. Thrombolysis was determined by clot mass loss and by RBC release. The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. Clot age did not affect rt-PA-induced thrombolysis but 2-hours-old clots were degraded more readily due to higher activity of spontaneous thrombolysis, as compared to 5-hours-old clots. Finally, heparin (50 and 100 IU/ml) did not influence the rt-PA-induced thrombolysis. Our study provided in vitro evidence for a clot size threshold: clots larger than 50 μl are hard to degrade by rt-PA. Increasing rt-PA concentration provided limited thrombolytic efficacy improvement, whereas heparin addition had no effect. However, the higher susceptibility of younger clots to thrombolysis may prompt a shortened time from the onset of stroke to rt-PA treatment.
Návaznosti
| MUNI/A/1598/2023, interní kód MU |
| ||
| NU22-08-00124, projekt VaV |
|